Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials

Reuters

08/12

<a href="https://laohu8.com/S/CLYM">Climb Bio</a> Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials

Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy (pMN) and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy (IgAN) in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510423-en) on August 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558649175"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558649175\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558649175?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558649175","market":"fut","top_or_hot":-1,"title":"Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy (pMN) and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy (IgAN) in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510423-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CLYM\">Climb Bio</a> Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy (pMN) and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy (IgAN) in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510423-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL5z29dN:1","article_id":"2558649175","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558649175","pubTimestamp":1754996493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials. Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy  and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy  in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","CLYM":"CLIMB BIO INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4539":"次新股","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Climb Bio Inc.获得PMN 2期试验和1期皮下Budoprutug试验的监管许可，ITP和SLE临床试验正在招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9,"NDAQ":0.9},"content_text":"Climb Bio Inc. Receives Regulatory Clearance for pMN Phase 2 Trial and Phase 1 Subcutaneous Budoprutug Trial, Enrollment Ongoing in ITP and SLE Clinical Trials\n    \n\n        Climb Bio Inc., a clinical-stage biotechnology company, has announced significant regulatory milestones in their ongoing efforts to advance treatments for immune-mediated diseases. The company has achieved regulatory clearance to initiate the Phase 2 trial of budoprutug for Primary Membranous Nephropathy (pMN) and the Phase 1 trial of subcutaneous budoprutug in healthy volunteers. These trials are expected to commence shortly, marking a step forward in Climb Bio's pipeline development. Additionally, Climb Bio is preparing for an IND or CTA submission for IgA Nephropathy (IgAN) in the second half of 2025. These advancements underscore Climb Bio's commitment to bringing innovative treatments to patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510423-en) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}